A team of US researchers has found that hormone therapy, when taken within six years of menopause, may slow the progression of subclinical atherosclerosis -- the primary underlying pathway that leads to heart disease and stroke.
The findings suggest that after a median of five years of hormone therapy, women in the early post-menopausal group who were taking estradiol, showed significantly less rate of blocked arteries -- a condition that can lead to heart disease and stroke, when measured against those taking the placebo.
"Studies on hormone therapy and vascular degeneration, provides strong evidence that the cardiovascular benefits of hormone therapy are dependent on timing of initiation," said Howard N. Hodis from Keck School of Medicine at the University of Southern California in the US.
The researchers examined the hypothesis that the cardiovascular effects of post-menopausal hormone therapy vary with the timing of hormone therapy initiation.
The team conducted a study, published in the New England Journal of Medicine, Early versus Late Intervention Trial with Estradiol (ELITE) in over 600 post-menopausal women with no history of cardiovascular disease or diabetes.
They were stratified into two groups: early post-menopause -- women who were within six years of menopause and late post-menopause -- women who were 10 years or more beyond menopause.
Women in each group were randomly assigned to receive either oral estradiol -- with progesterone vaginal gel for those with a uterus or a placebo -- which included a placebo vaginal gel for those with a uterus.
"ELITE provides proof of concept and first direct evidence from human investigation that timing of hormone therapy is imperative for success in the prevention of atherosclerosis progressio," Hodis added.
"The stratification of participants into early and late post-menopause was a unique feature of ELITE. We believe that applying this design to further examination of heart disease prevention could ultimately prove immensely fruitful for women's health," Hodis noted.
The concept of timing of initiation of an intervention is likely applicable to most preventive approaches to cardiovascular disease in women, the authors stated.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
